Concert Pharmaceuticals gains post-IPO

|By:, SA News Editor

In yet another biotech offering, Concert Pharmaceuticals (CNCE) is at $15.75 in opening trades after pricing its IPO at the top end of the expected $12-$14 range. The IPO size was also bumped to 6M from 5M shares.

In a similar business but further along in clinical trials is Auspex Pharmaceuticals (ASPX +5.7%), which priced its IPO (also after boosting the size) at $12 a week ago and has about doubled since.

More here